Acurx Pharmaceuticals Files 8-K on Agreements and Equity Sales
Ticker: ACXP · Form: 8-K · Filed: May 8, 2025 · CIK: 1736243
Sentiment: neutral
Topics: material-agreement, equity-sale, filing
Related Tickers: ACRX
TL;DR
ACRX filed an 8-K detailing new agreements and equity sales. Keep an eye on this.
AI Summary
Acurx Pharmaceuticals, Inc. filed an 8-K on May 8, 2025, reporting on the entry into a material definitive agreement and unregistered sales of equity securities. The filing also includes financial statements and exhibits. The company is incorporated in Delaware and its principal executive offices are located at 259 Liberty Avenue, Staten Island, NY.
Why It Matters
This 8-K filing indicates significant corporate actions by Acurx Pharmaceuticals, including definitive agreements and equity transactions, which could impact its financial structure and future operations.
Risk Assessment
Risk Level: medium — Filings related to material definitive agreements and unregistered equity sales can indicate significant corporate changes or financing activities that may carry inherent risks.
Key Players & Entities
- Acurx Pharmaceuticals, Inc. (company) — Registrant
- May 8, 2025 (date) — Date of earliest event reported
- 259 Liberty Avenue, Staten Island, NY 10305 (location) — Principal executive offices
- Delaware (jurisdiction) — State of incorporation
FAQ
What type of material definitive agreement did Acurx Pharmaceuticals enter into?
The filing does not specify the exact nature of the material definitive agreement, only that one was entered into.
What was the purpose of the unregistered sales of equity securities?
The filing does not provide details on the purpose of the unregistered sales of equity securities.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on May 8, 2025.
Where are Acurx Pharmaceuticals' principal executive offices located?
Acurx Pharmaceuticals' principal executive offices are located at 259 Liberty Avenue, Staten Island, NY 10305.
What is Acurx Pharmaceuticals' fiscal year end?
Acurx Pharmaceuticals' fiscal year ends on December 31 (1231).
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on May 8, 2025 regarding Acurx Pharmaceuticals, Inc. (ACXP).